Publicaciones en colaboración con investigadoras/es de University of Pisa (20)

2023

  1. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  2. Evaluating the Construct of Damage in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 75, Núm. 5, pp. 998-1006

  3. Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases

    The Lancet Rheumatology

2022

  1. Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic

    Lupus Science and Medicine, Vol. 9, Núm. 1

2021

  1. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

    Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552

  2. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies

    Lupus Science and Medicine, Vol. 8, Núm. 1

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to extended-spectrum-beta-lactamase-producing enterobacterales in kidney transplant recipients

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 11

  5. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts

    Lupus Science and Medicine, Vol. 8, Núm. 1

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

  2. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

    The Lancet, Vol. 396, Núm. 10264, pp. 1745-1757

  3. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

  4. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

    American Journal of Transplantation, Vol. 20, Núm. 6, pp. 1629-1641

2019

  1. EULAR recommendations for the management of antiphospholipid syndrome in adults

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 10, pp. 1296-1304

  2. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 634-640

  3. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 5, Núm. 3, pp. 202-207

2018

  1. Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome

    Gastroenterology, Vol. 155, Núm. 1, pp. 168-179

  2. Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients

    Clinical Gastroenterology and Hepatology

  3. Tacrolimus in non-Asian patients with SLE: A real-life experience from three European centres

    Lupus Science and Medicine, Vol. 5, Núm. 1

2013

  1. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients

    ARTHRITIS AND RHEUMATISM